POLL: Do Your Patients Need Better Sun Protection Resources?

Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.

Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.

Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.

Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.